Biotech News

GoodRx Powers Pricing for Leading Brand Medications on TrumpRx

GoodRx (GDRX)GoodRx2026-02-06 00:44 ESTCommercial

Brief Summary: GoodRx is a core integration partner for TrumpRx, powering the pricing for leading brand medications At launch, GoodRx is the integrated pricing source on TrumpRx for Pfizer, including over 30 of Pfizer’s essential brand medications spanning women’s health, arthritis, and more By

Open original release

Related news

GDRXGoodRx2026-05-27 13:00 EST

GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs

GDRXGoodRx2026-05-06 20:05 EST

GoodRx Reports First Quarter 2026 Results

GDRXGoodRx2026-05-01 12:10 EST

GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients

GDRXGoodRx2026-04-17 20:05 EST

GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call

GDRXGoodRx2026-04-15 13:00 EST

GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price

GDRXGoodRx2026-04-09 11:30 EST

GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide

GDRXGoodRx2026-03-11 13:00 EST

GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications

GDRXGoodRx2026-03-06 14:00 EST

GoodRx to Expand Employer-Sponsored Access to Zepbound® KwikPen®

GDRXGoodRx2026-02-25 21:05 EST

GoodRx Reports Fourth Quarter and Full Year 2025 Results

GDRXGoodRx2026-02-24 14:00 EST

GoodRx Expands Into Employer Market With Launch of “GoodRx Employer Direct”

View all latest news

GoodRx

GoodRx is a consumer healthcare platform focused on drug pricing, pharmacy access, and savings tools for patients.

Recent company news

GDRXBruker2026-07-24 20:01 EST

Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

GDRXQuest Diagnostics2026-07-23 10:45 EST

Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

GDRXMolina Healthcare2026-07-22 20:15 EST

Molina Healthcare Reports Second Quarter 2026 Financial Results

GDRXAxon Enterprise, Inc.2026-07-22 20:01 EST

Axon to Release Second Quarter 2026 Earnings on August 5, 2026

GDRXGSK plc2026-07-22 11:21 EST

Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

Stock data

Close: 2.87 USD
Market cap: 999.09M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States